Canada’s Drug Agency is seeking up to 2 expert members to join our Formulary Management Expert Committee (FMEC). The nomination period closes March 30, 2026.

We are particularly interested in receiving nominations from medical oncologists, hematologists, and other clinicians with expertise in the treatment of pediatric patients and/or adult patients.

Expert members on FMEC bring the following qualifications to the committee:

• a professional degree in medicine from a recognized institution
  
• in active practice and/or conducting research in either the community, hospital, and/or academic setting; or, if not in active practice, remains engaged in patient care and clinical practice
  
• an understanding of the use and delivery of drugs within the context of health care systems in Canada.
  

FMEC is composed of individuals with expertise in drug therapy, drug evaluation, and drug utilization, as well as patient representatives. The committee issues recommendations for nonsponsored single drug reviews, streamlined drug class reviews, therapeutic reviews, and other types of drug reviews as requested by federal, provincial, and territorial governments (except Quebec); drug plans; and cancer agencies. These recommendations are intended to increase the likelihood that reviews across the pharmaceutical life cycle will result in system impact.

Under its mandate, FMEC also trials innovative approaches to health technology assessment before their broader adoption by the organization’s other expert committees.

Click here to view the complete role description. Visit the website of Canada’s Drug Agency for complete details and to submit a nomination using their online form.